Millipore Sigma Vibrant Logo

508340 InSolution™ PERK Inhibitor I, GSK2606414 - CAS 1337531-89-1 - Calbiochem

InSolution™ PERK Inhibitor I, GSK2606414 - CAS 1337531-89-1 - Calbiochem: のSDS（安全データシート）、CoA（試験成績書）およびCoQ（品質証明書）、カタログなど製品関連の技術資料を入手いただけます。

同義語: 1-(5-(4-Amino-7-methyl-7H-pyrrolo[2,3-d]pyrimidin-5-yl)indolin-1-yl)-2-(3-(trifluoromethyl)phenyl)ethanone, 7-Methyl-5-(1-((3-trifluoromethyl)phenyl)acetyl)-2,3-dihydro-1H-indol-5-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine

Primary Target: PERK
508340
価格＆在庫状況を照会

概要

Replacement Information

主要スペック表

CAS #Empirical Formula
1337531-89-1C₂₄H₂₀F₃N₅O

価格＆在庫状況

カタログ番号 在庫状況包装 Qty/Pk 価格 数量
5.08340.0001
在庫状況検索中…
—
現在国内在庫なし 現在国内在庫なし
現在国内在庫有り 
販売中止
在庫僅少
現在国内在庫あり
    Remaining : Will advise
      Remaining : Will advise
      注文対象外
      お問合せください
      Contact Customer Service

      		 ｶﾞﾗｽﾋﾞﾝ 2 mg
      価格を検索中…
      価格が見つかりません
      Minimum Quantity needs to be mulitiple of
      Maximum Quantity is
      弊社照会 詳細を表示　
      値引
      ()
       
      —
      弊社照会
      		 —
      Description
      Catalogue Number508340
      Brand Family Calbiochem®
      Synonyms1-(5-(4-Amino-7-methyl-7H-pyrrolo[2,3-d]pyrimidin-5-yl)indolin-1-yl)-2-(3-(trifluoromethyl)phenyl)ethanone, 7-Methyl-5-(1-((3-trifluoromethyl)phenyl)acetyl)-2,3-dihydro-1H-indol-5-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine
      References
      ReferencesAxten, J.M., et al. 2012. J. Med. Chem. 55, 7193.
      Product Information
      CAS number1337531-89-1
      FormLiquid
      FormulationA 25 mM (2 mg/177 µL) sterile-filtered solution of PERK Inhibitor I, GSK2606414 (Cat. No. 516535) in DMSO.
      Hill FormulaC₂₄H₂₀F₃N₅O
      Chemical formulaC₂₄H₂₀F₃N₅O
      Hygroscopic Hygroscopic
      ReversibleY
      Structure formula ImageStructure formula Image
      Quality LevelMQ100
      Applications
      Biological Information
      Primary TargetPERK
      Purity≥98% by HPLC
      Physicochemical Information
      Cell permeableY
      Dimensions
      Materials Information
      Toxicological Information
      Safety Information according to GHS
      Safety Information
      Product Usage Statements
      Storage and Shipping Information
      Ship Code Dry Ice Only
      Toxicity Standard Handling
      Storage ≤ -70°C
      Protect from Light Protect from light
      Hygroscopic Hygroscopic
      Avoid freeze/thaw Avoid freeze/thaw
      Do not freeze Ok to freeze
      Special InstructionsFollowing initial thaw, aliquot and freeze (-20°C). Aliquots are stable for up to 6 months at -20°C. Use only fresh DMSO for further dilutions.
      Packaging Information
      Packaged under inert gas Packaged under inert gas
      Transport Information
      Supplemental Information
      Specifications
      Global Trade Item Number
      カタログ番号 GTIN
      5.08340.0001 04055977261912

      Documentation

      参考資料

      参考資料の概要
      Axten, J.M., et al. 2012. J. Med. Chem. 55, 7193.
      データシート

      Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

      Revision13-December-2013 JSW
      Synonyms1-(5-(4-Amino-7-methyl-7H-pyrrolo[2,3-d]pyrimidin-5-yl)indolin-1-yl)-2-(3-(trifluoromethyl)phenyl)ethanone, 7-Methyl-5-(1-((3-trifluoromethyl)phenyl)acetyl)-2,3-dihydro-1H-indol-5-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine
      DescriptionA cell-permeable pyrrolopyrimidinamine compound that acts as a highly potent inhibitor against EIF2AK3/PERK-catalyzed EIF2α Ser51 phosphorylation in kinase assays (IC50 = 0.4 nM; 30 min preincubation; [ATP] = 5 µM) as well as ER stress-induced PERK autophosphorylation following Thapsigargin (Cat. No. 586005) addition in A549 cultures (by 100% with ≤30 nM inhibitor; 60 min preincubation) by targeting PERK in its inactive conformation at the ATP-binding region. Displays ≥385-fold selectivity over c-Kit, Aurora B, BRK, HRI/EIF2AK1, MLK2/MAP3K10, c-MER, DDR2, PKR/EIF2AK2, and MLCK2/MYLK2 (IC50 = 154, 407, 412, 420, 452, 474, 524, 696, and 701 nM, respectively) and exhibits much reduced or little activity against more than 280 other kinases (IC50 >1 µM). Reported to be orally available in dog, mouse, and rat with good pharmacokinetics and retard the growth of established PxBC-3 tumor mass in mice in vivo (by 20% and 59% at the end of a 21 day treatment period with b.i.d. oral dosage of 50 and 150 mg/kg, respectively). The preincubation time-dependent inhibition, extremely slow dissociation rate, as well as the observed PERK selectivity, are all consistent with the inhibitor targeting PERK in its inactive DFG conformation.
      FormLiquid
      FormulationA 25 mM (2 mg/177 µL) sterile-filtered solution of PERK Inhibitor I, GSK2606414 (Cat. No. 516535) in DMSO.
      Intert gas (Yes/No) Packaged under inert gas
      CAS number1337531-89-1
      Chemical formulaC₂₄H₂₀F₃N₅O
      Structure formulaStructure formula
      Purity≥98% by HPLC
      Storage Protect from light
      Avoid freeze/thaw
      ≤ -70°C
      Hygroscopic
      Do Not Freeze Ok to freeze
      Special InstructionsFollowing initial thaw, aliquot and freeze (-20°C). Aliquots are stable for up to 6 months at -20°C. Use only fresh DMSO for further dilutions.
      Toxicity Standard Handling
      ReferencesAxten, J.M., et al. 2012. J. Med. Chem. 55, 7193.